On June 4, 2021, the U.S. Food and Drug Administration (FDA) approved marketing of Wegovy™, a new injected drug treatment for chronic weight management in people with a body mass index of 27 kg/m2 or higher who have at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol). Novo Nordisk, which developed the medication, expects to launch Wegovy™ in the United States later in June 2021. Wegovy™ is the U.S. brand name for a once-weekly semaglutide 2.4 mg injection. The medication is approved for use as an adjunct . . .